London launches extensive trial on Aspirin's ability of preventing cancer relapse

This entry passed through the Full-Text RSS service - if this is your content and you're reading it on someone else's site, please read the FAQ at http://ift.tt/jcXqJW.

Friday 23 Oct 2015 - 22:14 Makkah mean time-10-1-1437 (Image from Shutterstock) London, (IINA) - For years, studies have shown that aspirin may assist in deterring cancer or its recurrence. Researchers have declared the beginning of a large and long-term study, which aims at investigating whether the painkiller's anti-cancer effects may lead to a medical revolution, UPI reported. Cancer Research UK and the British National Institute for Health Research are launching the "Add-Aspirin Phase III" trial, and they are planning to recruit more than 11,000 patients who were treated or are being treated for bowel, breast, esophageal, prostate or stomach cancer. The study could run for as long as 12 years as researchers monitor the effects of daily aspirin use for five years on cancer. "There's been some interesting research suggesting that aspirin could delay or stop early stage cancers [from] coming back, but there's been no randomized trial to give clear proof", said Ruth Langley, a professor at University College London. "This trial aims to answer this question once and for all. If we find that aspirin does stop these cancers [from] returning, it could change future treatment, providing a cheap and simple way to help stop cancer coming back and helping more people survive". Researchers plan to split participants into three groups: one-third of the participants will receive a 300 mg aspirin tablet each day, one-third will be given 100 mg tablets, and the rest will receive a placebo. Doctors and patients will not be told which of the treatments the participants are given. The participants will be carefully monitored for any effects on their health, most significantly whether their cancer has come back. Researcher at Royal Marsden NHS Trust Alistair Ring stressed: "Unless you are on the trial, it's important not to start taking aspirin until we have the full results as aspirin isn't suitable for everyone, and it can have serious side effects". AG/IINA